Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 4Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Metastatic Solid Tumors 2Melanoma 2Solid Tumors 1Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Recurrence 1Prostate Cancer Patients Undergoing Radical Prostatectomy 1Neoplasms 1Neoadjuvant Treatment for Locally Advanced Cervical Cancer 1Myeloproliferative Disorders 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Cancer Pain 1Breast Neoplasms 1Breakthrough Pain 1Biliary Tract Neoplasms 1Advanced Malignant Neoplasm 1

Interventions

Pemetrexed 1Injections, Subcutaneous 1Infusions, Intravenous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer × Infusions, Intravenous × Clear all
NCT06505837 2025-08-28

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer(NSCLC)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Active not recruiting
395 enrolled
Thoracic

Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡